All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Neuralstem Inc. shares (NYSE:CUR) crumpled on Thursday, falling 36.6 percent in heavy trading to close at $2.37 as investors mulled top-line data from a phase II dose-escalation trial of NSI-566, the company's experimental neural stem cell therapy for amyotrophic lateral sclerosis (ALS).